Breaking up isn’t so hard to do, it seems. Just two years after spinning off its consumer products as Kenvue Inc., Johnson & Johnson aims to part ways with its orthopedics unit, which will take up the Depuy Synthes name first created when Synthes Inc. married into the J&J Depuy ortho unit in 2012 for a tidy sum of $19.7 billion. Depuy was itself acquired in 1998. Read More
Private equity firm Keensight Capital acquired a majority stake in Bedfont Scientific Ltd. in a move that will allow the company to expand the use of its devices for breath analysis and monitoring worldwide. Although the value of the deal was undisclosed, Keensight typically invests in profitable companies generating revenues in the range of €10 million to €400 million. Read More
Digital mental health tools are popping up with some regularity lately, but both Australia’s Therapeutic Goods Administration and the U.S. FDA have enough concerns about these products that they are taking a closer look at their risks and benefits. Read More
Histosonics Inc. signed an exclusive distribution agreement with Gunze Medical Ltd. to bring its novel histotripsy-based therapeutic model, the Edison System, to Japan. The strategic alliance with Gunze Medical, a wholly owned subsidiary of Osaka, Japan-based Gunze Ltd., paves a figurative runway for Histosonics to introduce its Edison platform in Japan — one of Asia’s largest medical device markets. Read More
Patent litigation doesn’t always create outlandish damages awards but when it does, the outlandishness typically trends toward inordinately large sums. This was decidedly not the case in the Federal Circuit hearing in a patent lawsuit pitting Intuitive Surgical Inc., of Sunnyvale, Calif., against Rex Medical LP, of Conshohocken, Pa., given the damages awarded to Rex amounted to a mere $1. Read More
Oura Health Oy raised more than $900 million in a series E funding round to fuel global expansion of its popular smart ring and development of new health technologies. The new infusion brings the company’s total funds raised to date to $1.5 billion and implies a corporate valuation of about $11 billion, Oura said. Read More
New hires and promotions in the med-tech industry, including: Avantor, Deep Genomics, Depuy Synthes, Gene Dx, Insight Molecular, J&J, Nextsense, Oura. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Clarity Pharmaceuticals, Establishment Labs. Read More
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: AML, Autogen, Ciliatech, Cortechs.ai, Levee Medical, Microbot Medical, OSR Holdings, Refinedscience, Sampled, UCHealth, Verily, Woori, Zepmed. Read More
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Biolytical Labs, Centinel Spine, Medtronic, Relu.ai, Simergent. Read More
